The Society of Hospital Pharmacists of Australia (SHPA) has welcomed new federal government legislation to further mitigate the impact of medicine shortages on Australians and ensure new and innovative medicines are accessible, available and affordable.
As we live through the lengthening tail of a persistent pandemic, it is challenging to consider the simpler medicines landscape of 20 years ago.
While antimicrobial use in the community is decreasing, overprescribing and inappropriate prescribing continue to be problematic.
For the first time since its development in 1999, Australia's National Medicines Policy is set for review.
Accelerating the rollout of vaccines into pharmacies could help Australia reach its vaccination target of 80% up to two months faster than current projections.
Medibis has announced long-term plans to build a multi-million-dollar medicinal cannabis facility in Toowoomba, Queensland.
Reduced levels of the metabolic hormone leptin may be responsible for poor vaccine efficacy among certain individuals, according to a new study.
An Adelaide-based company has developed a COVID-19 vaccine that completely blocks viral transmission to individuals who lack immunity, as well as offering protection for those inoculated.
Epidyolex has been added to the Pharmaceutical Benefits Scheme (PBS) for the treatment of Dravet syndrome, a rare and drug-resistant form of epilepsy.
The standardised guidelines place pharmacists as key members of the multidisciplinary medical team caring for patients in the ICU.
Researchers at the Cochrane Collaboration reviewed 33 studies involving nearly 5000 participants, relating to antidepressant discontinuation.
SHPA will continue to advocate for investment in embedding geriatric medicine pharmacists as part of clinical pharmacy services for aged-care residents.
Johnson & Johnson Innovation has facilitated a collaboration between WEHI and Janssen Pharmaceutica NV to ignite the development of antimalarial drug candidates.
Australians are being reminded that a causal relationship between blood clotting and adenovirus vector-based vaccines has still not been established, and that — should it be — the risk remains far lower than that of common medications.
This winter, for the first time, a new cell-based flu vaccine will be introduced in Australia, in a bid to boost the efficacy rates of national immunisation programs.